MarvelBiome
Elam completed his Ph.D. from Max-Planck Institute in Germany in the area of anaerobic microbiology. His Ph.D. research was focused on the metabolic pathways leading to short chain fatty acids production (metabolites) in anaerobic bacteria. In his postdoctoral research at Professor Ruvkun’s lab at MGH / Harvard Medical School, Elam isolated the microbes that have evolved to target specific host pathways, to benefit the host’s physiology and metabolism. Elam has over 20 publications in high impact journals including Nature Cell Biology, PNAS, Journal of Bacteriology, and Antimicrobial Agents and Chemotherapy.
MarvelBiome
MarvelBiome is a biopharmaceutical company with a vision of harnessing the power of microbes for treating various human diseases. It focuses on isolating, identifying, and characterizing microbial populations for novel therapeutic applications.